Company Encyclopedia
View More
name
Direxion S&P Biotech Bull 3X
LABU.US
News
View More

Rhumbline Advisers Reduces Holdings in Revolution Medicines, Inc. $RVMD

Rhumbline Advisers reduced its holdings in Revolution Medicines, Inc. by 39.1% in Q2, owning 156,591 shares worth $5.76 million. Other institutional investors adjusted their stakes, with 94.34% of the stock owned by institutions. Insiders sold 308,033 shares worth $17.08 million in the last 90 days. Analysts have given the stock a consensus 'Buy' rating with an average price target of $78.50. Revolution Medicines' stock rose 3.2%, opening at $77.69, with a market cap of $15.02 billion.

Market Beat·
US
RVMD
+1.48%
Market Beat·
US
RVMD
+1.48%

Promising Outlook for Revolution Medicines: Buy Rating Backed by Pivotal Trials and Market Potential

TD Cowen analyst Marc Frahm maintains a Buy rating on Revolution Medicines (RVMD) due to promising pivotal trials and market potential, particularly in second-line pancreatic ductal adenocarcinoma (PDAC). The company's lead candidate, daraxonrasib, is in trials for various cancers, with positive expectations. Frahm, a 5-star analyst, anticipates significant market growth, potentially elevating RVMD's market cap to over $20 billion. J.P. Morgan also supports a Buy rating with an $82 price target.

Tip Ranks·
US
RVMD
+1.48%
Tip Ranks·
US
RVMD
+1.48%

18:59 ET Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws by Avidity Biosciences, Third Coast Bancshares, Astria Therapeutics, and FirstSun Capital Bancorp. The firm encourages shareholders to contact them to discuss their rights, as they may seek increased consideration, additional disclosures, or other relief on behalf of shareholders. The firm operates on a contingent fee basis, representing investors worldwide in securities fraud and corporate misconduct cases.

prnewswire·
US
RNA
+0.13%
US
ATXS
-1.45%
prnewswire·
US
RNA
+0.13%
US
ATXS
-1.45%

15:20 ET $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN

Monteverde & Associates PC is investigating mergers involving Third Coast Bancshares, Avidity Biosciences, Astria Therapeutics, and FirstSun Capital Bancorp. Keystone shareholders may receive shares or cash from Third Coast, Avidity shareholders $72 per share from Novartis, Astria shareholders cash and shares from BioCryst, and FirstSun shareholders will own 59.5% of the merged company with First Foundation. The firm, recognized for recovering millions for shareholders, offers free information and legal inquiries.

prnewswire·
US
ATXS
-1.45%
US
RNA
+0.13%
prnewswire·
US
ATXS
-1.45%
US
RNA
+0.13%

This Top Dividend King Just Became an Even Better Buy

Abbott Laboratories announced the acquisition of Exact Sciences for $21 billion, enhancing its diagnostics business. This move allows Abbott to expand Exact Sciences' innovative cancer diagnostic products globally, leveraging its resources and international presence. Abbott's acquisition grants access to a lucrative cancer diagnostics market, complementing its strong growth prospects and dividend program. Abbott's diversified portfolio and innovative capabilities make it an attractive investment, with its continuous glucose monitoring systems and structural heart segment offering long-term growth potential.

Yahoo Finance·
US
ABT
-0.26%
US
EXAS
-0.07%
Yahoo Finance·
US
ABT
-0.26%
US
EXAS
-0.07%
Posts
View More

$Direxion S&P Biotech Bull 3X(LABU.US)You're even stronger than AI, hitting new highs without any pullback these two weeks

  • 0

It took two months to go from 100% to 200%.$AMD(AMD.US)$Alphabet(GOOGL.US)$Direxion S&P Biotech Bull 3X(LABU.US)

  • 0

Under the pressure of interest rate cuts, small-cap stocks like $SPDR S&P Biotech(XBI.US) are rising much faster than large-cap stocks like $Alphabet(GOOGL.US)😂

  • 0

The impact of interest rate cuts on small and mid-cap biotech stocks in the US market is immediate$Direxion S&P Biotech Bull 3X(LABU.US)$SPDR S&P Biotech(XBI.US)

  • 0

Adjusting the portfolio again, cutting $AMD(AMD.US) in half. Chasing some $SPDR S&P Biotech(XBI.US)$Direxion S&P Biotech Bull 3X(LABU.US), waiting for the market to continue trading on rate cut and re...

  • 0
© 2025 Longbridge｜Disclaimer